{
  "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "docSlug": "5062b9a9257606648ea145bccd66e04d",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 41,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The chart visualizes the dominance of Alectinib and Crizotinib in the current market landscape.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/11",
  "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "deckJsonHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json",
  "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.5,
        "x": 0.45,
        "y": 0.12
      },
      "kind": "chart",
      "text": "2022 GLOBAL SALES FOR ALK & ROS1 TKIs",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86d6ce9f-a31d-4afe-ae53-2f47ce980a7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "list",
      "text": "Potential best-in-class profiles designed with the goal to supplant the current 1L standard of care; Potential near-term registrational opportunity for TKI-pretreated patients; Potential to grow the market through deeper, more durable responses",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "837571e4-dbb4-447d-8203-888c7fe882b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.48,
        "y": 0.78
      },
      "kind": "source-note",
      "text": "1L, 1st line; 2L, 2nd line; 3L, 3rd line; B, billion; F, forecasted; M, million; NCCN, National Comprehensive Cancer Network; NSCLC, non-small cell lung cancer; PFS, progression-free survival; TKI, tyrosine kinase inhibitor. Sources: Cortellis Sales and Forecasts, accessed November 2023; FDA Package Inserts; NCCN Guidelines for NSCLC (version 5.2023).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f5e22e6-13cc-4bd8-aab4-225a0542d99d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "title",
      "text": "Meaningful Commercial Markets with ~$3B Combined WW Sales in 2022",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9b48d98-be8e-416c-aec5-eb366663f053",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "ALK+ & ROS1+ NSCLC Market Opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd1c37e5-1552-4b98-8f38-184cea9c1b4c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 11,
      "beatId": "7d7613a4-2fa9-47a2-8dd6-439e4bd4ffa2",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Sizing",
      "beatSlug": null,
      "evidence": "The document presents the market sizing for Nuvalent's therapies, highlighting the significant commercial opportunity.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7394c275-2e8b-4ce7-ac85-c375b43f1f48",
      "evidence": "The document highlights the limitations of current therapies and the potential benefits of Nuvalent's solutions.",
      "position": 0,
      "objective": "What are the consequences of not addressing the limitations of current cancer therapies?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}